Preclinical prophylactic efficacy testing of Sm-p80-based vaccine in a nonhuman primate model of schistosoma mansoni infection and immunoglobulin G and e responses to Sm-p80 in human serum samples from an area where schistosomiasis is endemic

Journal of Infectious Diseases

Volumn 204, Issue 9, 2011, Pages 1437-1449

  Ahmad, Gul ^a   Zhang, Weidong ^a   Torben, Workineh ^a   Ahrorov, Afzal ^a   Damian, Raymond T ^b   Wolf, Roman F ^b   White, Gary L ^c   Carey, David W ^c   Mwinzi, Pauline N M ^d   Ganley Leal, Lisa ^e   Kennedy, Ronald C ^a   Siddiqui, Afzal A ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^d KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; CPG OLIGODEOXYNUCLEOTIDE; DNA VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12P35; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 22; INTERLEUKIN 6; PRAZIQUANTEL; PROTEIN P80; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; RESIQUIMOD; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; VR 1020;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; BABOON; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; ENDEMIC DISEASE; FEMALE; HIGH RISK POPULATION; IMMUNOREACTIVITY; INFECTION RISK; MALE; NONHUMAN; PRIORITY JOURNAL; SCHISTOSOMIASIS MANSONI; TH1 CELL; TH17 CELL; TH2 CELL; UPREGULATION;

ANIMALS; ANTIBODIES, HELMINTH; ANTIGENS, HELMINTH; CYTOKINES; DISEASE MODELS, ANIMAL; ENDEMIC DISEASES; FEMALE; HUMANS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; MALE; PAPIO; PRIMATE DISEASES; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; SERUM; VACCINATION; VACCINES, DNA; VACCINES, SUBUNIT;

EID: 80053394818     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir545     Document Type: Article

References (49)

1. Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomiasis. Lancet 2006; 368:1106-18. (Pubitemid 44402679)
2. Hotez PJ, Molyneux DH, Fenwick A, et al. Control of neglected tropical diseases. N Engl J Med 2007; 357:1018-27. (Pubitemid 47367081)
3. Gray DJ, McManus DP, Li Y, Williams GM, Bergquist R, Ross AG. Schistosomiasis elimination: lessons from the past guide the future. Lancet Infect Dis 2010; 10:733-6.
4. King CH. Parasites and poverty: the case of schistosomiasis. Acta Trop 2010; 113:95-104.
5. Hotez PJ, Fenwick A. Schistosomiasis in Africa: an emerging tragedy in our new global health decade. PLoS Negl Trop Dis 2009; 3:e485.
6. Utzinger J, N'Goran EK, Caffrey CR, Keiser J. From innovation to application: social-ecological context, diagnostics, drugs and integrated control of schistosomiasis. Acta Trop 2010; doi:10.1016/j.actatropica. 2010.08.020.
7. Parker M, Allen T. Does mass drug administration for the integrated treatment of neglected tropical diseases really work? Assessing evidence for the control of schistosomiasis and soil-transmitted helminths in Uganda. Health Res Policy Syst 2011; 9:3.
8. Doenhoff MJ, Hagan P, Cioli D, et al. Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs. Parasitology 2009; 136:1825-35.
9. Bergquist R, Utzinger J, McManus DP. Trick or treat: the role of vaccines in integrated schistosomiasis control. PLoS Negl Trop Dis 2008; 2:e244.
10. McManus DP, Loukas A. Current status of vaccines for schistosomiasis. Clin Microbiol Rev 2008; 21:225-42. (Pubitemid 351160017)
11. Bergquist NR, Leonardo LR, Mitchell GF. Vaccine-linked chemotherapy: can schistosomiasis control benefit from an integrated approach? Trends Parasitol 2005; 21:112-7. (Pubitemid 40269774)
12. Bethony JM, Cole RN, Guo X, et al. Vaccines to combat the neglected tropical diseases. Immunol Rev 2011; 239:237-70.
13. Hotez PJ, Bethony JM, Diemert DJ, Pearson M, Loukas A. Developing vaccines to combat hookworm infection and intestinal schistosomiasis. Nat Rev Microbiol 2010; 8:814-814.
14. Siddiqui AA, Ahmad G, Damian RT, Kennedy RC. Experimental vaccines in animal models for schistosomiasis. Parasitol Res 2008; 102:825-33.
15. Braschi S, Wilson RA. Proteins exposed at the adult schistosome surface revealed by biotinylation. Mol Cell Proteomics 2006; 5:347-56. (Pubitemid 43329312)
16. Siddiqui AA, Zhou Y, Podesta RB, et al. Characterization of Ca(21)-dependent neutral protease (calpain) from human blood flukes, Schistosoma mansoni. Biochim Biophys Acta 1993; 1181:44-37.
17. Ahmad G, Zhang W, Torben W, et al. Prime-boost and recombinant protein vaccination strategies using Sm-p80 protects against Schistosoma mansoni infection in the mouse model to levels previously attainable only by the irradiated cercarial vaccine. Parasitol Res 2009; 105:1767-77.
18. Ahmad G, Torben W, Zhang W, Wyatt M, Siddiqui AA. Sm-p80-based DNA vaccine formulation induces potent protective immunity against Schistosoma mansoni. Parasite Immunol 2009; 31:156-61.
19. Ahmad G, Zhang W, Torben W, et al. Protective and antifecundity effects of Sm-p80-based DNA vaccine formulation against Schistosoma mansoni in a nonhuman primate model. Vaccine 2009; 27:2830-7.
20. Ahmad G, Zhang W, Torben W, Noor Z, Siddiqui AA. Protective effects of Sm-p80 in the presence of resiquimod as an adjuvant against challenge infection with Schistosoma mansoni in mice. Int J Infect Dis 2010; 14:e781-7.
21. Hota-Mitchell S, Siddiqui AA, Dekaban GA, Smith J, Tognon C, Podesta RB. Protection against Schistosoma mansoni infection with a recombinant baculovirus-expressed subunit of calpain. Vaccine 1997; 15:1631-40. (Pubitemid 27445743)
22. Hota-Mitchell S, Clarke MW, Podesta RB, Dekaban GA. Recombinant vaccinia viruses and gene gun vectors expressing the large subunit of Schistosoma mansoni calpain used in a murine immunization-challenge model. Vaccine 1999; 17:1338-54. (Pubitemid 29138800)
23. Siddiqui AA, Phillips T, Charest H, et al. Enhancement of Sm-p80 (large subunit of calpain) induced protective immunity against Schistosoma mansoni through co-delivery of interleukin-2 and interleukin-12 in a DNA vaccine formulation. Vaccine 2003; 21:2882-9. (Pubitemid 36703200)
24. Siddiqui AA, Phillips T, Charest H, et al. Induction of protective immunity against Schistosoma mansoni via DNA priming and boosting with the large subunit of calpain (Sm-p80): adjuvant effects of granulocyte-macrophage colony-stimulating factor and interleukin-4. Infect Immun 2003; 71:3844-18.
25. Siddiqui AA, Pinkston JR, Quinlin ML, et al. Characterization of protective immunity induced against Schistosoma mansoni via DNA priming with the large subunit of calpain (Sm-p80) in the presence of genetic adjuvants. Parasite 2005; 12:3-8. (Pubitemid 40431519)
26. Siddiqui AA, Pinkston JR, Quinlin ML, et al. Characterization of the immune response to DNA vaccination strategies for schistosomiasis candidate antigen, Sm-p80 in the baboon. Vaccine 2005; 23:1451-6. (Pubitemid 40164704)
27. Torben W, Ahmad G, Zhang W, Siddiqui AA. Role of antibodies in Sm-p80-mediated protection against Schistosoma mansoni challenge infection in murine and nonhuman primate models. Vaccine 2011; 29:2262-71.
28. Zhang W, Ahmad G, Torben W, et al. Sm-p80-based DNA vaccine provides baboons with levels of protection against Schistosoma mansoni infection comparable to those achieved by the irradiated cercarial vaccine. J Infect Dis 2010; 201:1105-2.
29. Zhang W, Ahmad G, Torben W, Siddiqui AA. Sm-p80-based DNA vaccine made in a human use approved vector VR1020 protects against challenge infection with Schistosoma mansoni in mouse. Parasite Immunol 2010; 32:252-2.
30. Zhang W, Ahmad G, Torben W, Siddiqui AA. Schistosoma mansoni antigen Sm-p80: prophylactic efficacy of a vaccine formulated in human approved plasmid vector and adjuvant (VR 1020 and alum). Acta Trop 2011; 118:142-51.
31. Cheng W, Shivshankar P, Zhong Y, Chen D, Li Z, Zhong G. Intracellular interleukin-1alpha mediates interleukin-8 production induced by Chlamydia trachomatis infection via a mechanism independent of type I interleukin-1 receptor. Infect Immun 2008; 76:942-51. (Pubitemid 351428053)
32. Villinger F, Brar SS, Mayne A, Chikkala N, Ansari AA. Comparative sequence analysis of cytokine genes from human and nonhuman primates. J Immunol 1995; 155:3946-54.
33. Wu H, Zhu B, Shimoishi Y, Murata Y, Nakamura Y. (-)-Epigallocatechin-3- gallate induces up-regulation of Th1 and Th2 cytokine genes in Jurkat T cells. Arch Biochem Biophys 2009; 483: 99-105.
34. Black CL, Muok EM, Mwinzi PN, et al. Increases in levels of schistosome-specific immunoglobulin E and CD23(1) B cells in a cohort of Kenyan children undergoing repeated treatment and reinfection with Schistosoma mansoni. J Infect Dis 2010; 202:399-405.
35. Griffith QK, Liang Y, Onguru DO, Mwinzi PN, Ganley-Leal LM. CD23-bound IgE augments and dominates recall responses through human naive B cells. J Immunol 2011; 186:1060-7.
36. Bergquist R. Prospects of vaccination against schistosomiasis. Scand J Infect Dis Suppl 1990; 76:60-71.
37. Todd CW, Colley DG. Practical and ethical issues in the development of a vaccine against schistosomiasis mansoni. Am J Trop Med Hyg 2002; 66:348-58. (Pubitemid 34810487)
38. Damian RT, de la Rosa MA, Murfin DJ, Rawlings CA, Weina PJ, Xue YP. Further development of the baboon as a model for acute schistosomiasis. Mem Inst Oswaldo Cruz 1992; 87(suppl 4):261-9.
39. Kennedy RC, Shearer MH, Hildebrand W. Nonhuman primate models to evaluate vaccine safety and immunogenicity. Vaccine 1997; 15:903-8. (Pubitemid 27287986)
40. Tangye SG, Ferguson A, Avery DT, Ma CS, Hodgkin PD. Isotype switching by human B cells is division-associated and regulated by cytokines. J Immunol 2002; 169:4298-306. (Pubitemid 35178202)
41. Avery DT, Bryant VL, Ma CS, de Waal MR, Tangye SG. IL-21-induced isotype switching to IgG and IgA by human naive B cells is differentially regulated by IL-4. J Immunol 2008; 181:1767-79.
42. GarraudO, Perraut R, Riveau G, Nutman TB. Class and subclass selection in parasite-specific antibody responses. Trends Parasitol 2003; 19:300-4.
43. Ohtani H, Wakui H, Komatsuda A, et al. Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy. Nephrol Dial Transplant 2004; 19:574-9. (Pubitemid 38263115)
44. Mattos AM, Almeida CS, Franken KL, et al. Increased IgG1, IFNgamma, TNF-alpha and IL-6 responses to Mycobacterium tuberculosis antigens in patients with tuberculosis are lower after chemotherapy. Int Immunol 2010; 22:775-82.
45. Kikuchi T, Hahn CL, Tanaka S, Barbour SE, Schenkein HA, Tew JG. Dendritic cells stimulated with Actinobacillus actinomycetemcomitans elicit rapid gamma interferon responses by natural killer cells. Infect Immun 2004; 72:5089-96. (Pubitemid 39223393)
46. Benwell RK, Lee DR. Essential and synergistic roles of IL1 and IL6 in human Th17 differentiation directed by TLR ligand-activated dendritic cells. Clin Immunol 2010; 134:178-87.
47. Ganley-Leal LM, Mwinzi PN, Cetre-Sossah CB, et al. Correlation between eosinophils and protection against reinfection with Schistosoma mansoni and the effect of human immunodeficiency virus type 1 coinfection in humans. Infect Immun 2006; 74:2169-76.
48. Oliveira-Prado R, Caldas IR, Teixeira-Carvalho A, et al. CD4 and CD8 distribution profile in individuals infected by Schistosoma mansoni. Scand J Immunol 2009; 69:521-8.
49. Karanja DM, Hightower AW, Colley DG, et al. Resistance to reinfection with Schistosoma mansoni in occupationally exposed adults and effect of HIV-1 co-infection on susceptibility to schistosomiasis: a longitudinal study. Lancet 2002; 360:592-6. (Pubitemid 35232192)